Agrochemicals company Astec Lifesciences announced Q1FY25 results: Financial Highlights: Company reported consolidated total income of Rs 70.3 crore in Q1FY25 as compared to Rs 144.6 crore in Q1FY24 Company reported consolidated EBITDA loss of Rs 45.3 crore in Q1FY25 as compared to profit of Rs 4.8 crore in the same period last year Commenting on the performance, N B Godrej, Chairman, Astec LifeSciences, said: Astec continued to face pricing and demand headwinds in the enterprise products on account of destocking of the inventory across key markets. Challenging external environment necessitated write down of inventory which also significantly impacted the margins of the enterprise portfolio. Also, global logistics issues resulted in delay in receipt of essential raw materials for our Contract Manufacturing (CDMO) product which resulted in deferral of volumes. This unfortunate situation further compressed overall profit margins. Result PDF